Ireland-based clinical research organisation giant Icon has completed its $143.5 million acquisition of Aptiv Solutions.

The latter is "a recognised leader in the design and execution of adaptive clinical trials for pharmaceutical and biotech customers", noted Icon, adding that it also has "in-depth experience in the management of medical device trials". Another attraction is Aptiv's Japanese subsidiary Niphix, "a full-service, oncology-focused CRO serving both Japanese and international customers".

Nuala Murphy, president of Icon's clinical research services, said that Aptiv’s adaptive trial capabilities, "combined with our existing technology platforms, such as Iconik and Firecrest, will further differentiate our services and help our customers take time and cost out of the development process". She added that its presence in Japan and medical devices "will also broaden our offerings in these markets".